Key facts
- Vestal Point Capital, LP filed SCHEDULE 13G/A for Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share (BCAX).
- Disclosed ownership: 9.2%.
- Date of event: 30 Jun 2025.
Vestal Point Capital, LP - 30 Jun 2025 SCHEDULE 13G/A Report for Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share (BCAX)
- Filing Manager
- Vestal Point Capital, LP
- Reporting Manager
- Vestal Point Capital, LP
- Symbol
- BCAX
- Shares outstanding
- 54,347,826 shares
- Disclosed Ownership
- 5,000,000 shares
- Ownership
- 9.2%
- Form type
- SCHEDULE 13G/A
- Filing time
- 14 Aug 2025, 15:57:11 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 15 May 2025
- Next filing
- 17 Feb 2026
- SEC
- View on sec.gov
Key filing fact
Vestal Point Capital, LP disclosed 9.2% ownership in Bicara Therapeutics Inc. Common Stock, par value $0.0001 per share (BCAX) on 30 Jun 2025.
Change
- Previous schedule filing date: 15 May 2025.
- Current filing was accepted on 14 Aug 2025, 15:57.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vestal Point Capital, LP | 9.2% | 5,000,000 | 0 | 5,000,000 | /s/ Ryan Wilder | By: Vestal Point Capital, LLC, General Partner, By: Ryan Wilder, Chief Investment Officer and Managing Partner | |
| Ryan Wilder | 9.2% | 5,000,000 | 0 | 5,000,000 | /s/ Ryan Wilder | Ryan Wilder, Individually |
CIK / CUSIP context first